Portfoliotracker

Innovent Biologics, Inc.

1801.HK · HKSE · Healthcare Biotechnology 73/100 B

85,80 HKD
▲ +1,90 (+2,26 %)
Closed delayed by 15 min
Price as of 17. 11. 09:08, fetched 17. 11. 15:08
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score73 / 100 Market cap146 mld. HKD P/E110,4 Forward P/E33,3 P/S9,3 P/B6,0 EV/EBITDA71,1 Dividend yield– FCF yield– EPS0,76 HKD Net margin7,8 % Return on equity7,0 % Beta0,37 Debt / equity0,11
52-week range 69,55 to 112,70
3-month average volume11,9 M

We do not have financial statements yet

The company reports in CNY, while the price is quoted in HKD. We do not convert statements between currencies yet, because the multiples (P/E, P/S and others) would come out wrong, so we do not show them here. You can see the price and its history above.

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection). In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.

Employees
8 754
Country
China
Data since
31. 10. 2018

Explore further

Similar companies 9926.HK2269.HK

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account